Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Droperidol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Lake Erie College of Osteopathic Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Droperidol on Prevention of Cannabis Hyperemesis Syndrome
Details : Droperidol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cannabinoid Hyperemesis Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 17, 2022
Lead Product(s) : Droperidol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Lake Erie College of Osteopathic Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable